FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 333:1437-1444 November 30, 1995 Number 22 Next

	Full Text PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Liedholm, H. PubMed Citation

ABSTRACT

Background Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed.

Methods We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements.

Results The women receiving alendronate had significant, progressive increases in bone mineral density at all skeletal sites, whereas those receiving placebo had decreases in bone mineral density. At three years, the mean (±SE) differences in bone mineral density between the women receiving 10 mg of alendronate daily and those receiving placebo were 8.8±0.4 percent in the spine, 5.9±0.5 percent in the femoral neck, 7.8±0.6 percent in the trochanter, and 2.5±0.3 percent in the total body (P<0.001 for all comparisons). The 5-mg dose was less effective than the 10-mg dose, and the regimen of 20 mg followed by 5 mg was similar in efficacy to the 10-mg dose. Overall, treatment with alendronate was associated with a 48 percent reduction in the proportion of women with new vertebral fractures (3.2 percent, vs. 6.2 percent in the placebo group; P = 0.03), a decreased progression of vertebral deformities (33 percent, vs. 41 percent in the placebo group; P = 0.028), and a reduced loss of height (P = 0.005) and was well tolerated.

Conclusions Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebral deformities, and height loss in postmenopausal women with osteoporosis.

Source Information

From the Department of Metabolic Disease, Beilinson Medical Center, Tel Aviv University, Petah-Tikva, Israel (U.A.L.); the San Diego Endocrine and Medical Clinic, San Diego, Calif. (S.R.W.); the Department of Medicine, Kaiser Franz Josef Hospital, Vienna, Austria (J.B.); Klinik der Fürstenhof, Bad Pyrmont, Germany (H.W.M.); Merck Research Laboratories, Rahway, N.J. (H.Q., T.C., A.C.S., A.L., R.V.S., L.J.H., D.B.K.); the Department of Research Services, Veterans Affairs Medical Center, Charleston, S.C. (N.H.B.); the Department of Endocrinology, School of Medicine, Catholic University of Chile, Santiago (J.R.-P.); the Department of Medicine, Medical College of Virginia, Richmond (R.W.D.); the Department of Rheumatology, Catholic University Leuven, Leuven, Belgium (J.D.); the Department of Medicine, University of Chicago, Chicago (M.F.); the Department of Endocrinology, Austin Hospital, Heidelberg, Australia (E.S.); and the Center for Osteoporosis Research, Creighton University, Omaha, Nebr. (R.R.R.). Presented in part at the 77th Annual Meeting of the Endocrine Society, Washington, D.C., June 14–17, 1995.

Address reprint requests to Dr. Liberman at Metabolic Diseases, Beilinson Medical Center, 49100, Petah-Tikva, Israel.

Full Text of this Article

Related Letters:

Alendronate in Postmenopausal Osteoporosis
Liedholm H., Linné A. B., McGrath H., Liberman U., Karpf D. B., Capizzi T.
Extract | Full Text  
N Engl J Med 1996; 334:733-735, Mar 14, 1996. Correspondence

Injury Prevention
Barach P., Richter E., Leistikow B. N., Karpf D. B., Rivara F. P., Grossman D. C., Cummings P.
Extract | Full Text  
N Engl J Med 1998; 338:132-133, Jan 8, 1998. Correspondence

This article has been cited by other articles:

• Capeci, C. M., Tejwani, N. C. (2009). Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy. JBJS 91: 2556-2561 [Abstract] [Full Text]  
• McNamara, L. M. (2009). Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 0: rsif.2009.0282v1-rsif20090282 [Abstract] [Full Text]  
• Cortet, B. (2009). Osteoporosis: from early fracture prevention to better bone health with strontium ranelate. Rheumatology (Oxford) 48: iv14-iv19 [Abstract] [Full Text]  
• Wimalawansa, S. J., Grimes, J. P., Wilson, A. C., Hoover, D. R. (2009). Transdermal Nitroglycerin Therapy May Not Prevent Early Postmenopausal Bone Loss. J. Clin. Endocrinol. Metab. 94: 3356-3364 [Abstract] [Full Text]  
• STOCH, S. A., SAAG, K. G., GREENWALD, M., SEBBA, A. I., COHEN, S., VERBRUGGEN, N., GIEZEK, H., WEST, J., SCHNITZER, T. J. (2009). Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial. The Journal of Rheumatology 36: 1705-1714 [Abstract] [Full Text]  
• Farley, J. F., Blalock, S. J. (2009). Trends and determinants of prescription medication use for treatment of osteoporosis. Am J Health Syst Pharm 66: 1191-1201 [Abstract] [Full Text]  
• Burnett-Bowie, S.-A. M., Saag, K., Sebba, A., de Papp, A. E., Chen, E., Rosenberg, E., Greenspan, S. L. (2009). Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates. J. Clin. Endocrinol. Metab. 94: 1097-1103 [Abstract] [Full Text]  
• Compston, J. (2009). Is Monitoring Osteoporosis Therapy Worthwhile?. IBMS BoneKEy 6: 99-106 [Abstract] [Full Text]  
• Qaseem, A., Shekelle, P., Owens, D. K. (2009). Is Too Much Intervention Recommended in the ACP Osteoporosis Treatment Guidelines?. ANN INTERN MED 150: 286-287 [Full Text]  
• Hegge, K. A., Fornoff, A. S., Gutierres, S. L., Haack, S. L. (2009). New Therapies for Osteoporosis. Journal of Pharmacy Practice 22: 53-64 [Abstract]  
• Weinstein, R. S., Roberson, P. K., Manolagas, S. C. (2009). Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy. NEJM 360: 53-62 [Abstract] [Full Text]  
• CAREY, J. J., PALOMO, L. (2008). Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?. Cleveland Clinic Journal of Medicine 75: 871-879 [Abstract] [Full Text]  
• McGee-Lawrence, M. E., Carey, H. V., Donahue, S. W. (2008). Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295: R1999-R2014 [Abstract] [Full Text]  
• SINGER, F. R., EYRE, D. R. (2008). Using biochemical markers of bone turnover in clinical practice. Cleveland Clinic Journal of Medicine 75: 739-750 [Abstract] [Full Text]  
• Rabenda, V., Vanoverloop, J., Fabri, V., Mertens, R., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., Reginster, J.-Y. (2008). Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture. JBJS 90: 2142-2148 [Abstract] [Full Text]  
• Lester, J. E., Dodwell, D., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., Brown, J. E., Hannon, R. A., Coleman, R. E. (2008). Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clin. Cancer Res. 14: 6336-6342 [Abstract] [Full Text]  
• Drake, M. T., Clarke, B. L., Khosla, S. (2008). Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clin Proc. 83: 1032-1045 [Abstract] [Full Text]  
• Visekruna, M., Wilson, D., McKiernan, F. E. (2008). Severely Suppressed Bone Turnover and Atypical Skeletal Fragility. J. Clin. Endocrinol. Metab. 93: 2948-2952 [Abstract] [Full Text]  
• Kasai, S., Li, F., Shiraishi, J., Doi, K. (2008). Usefulness of Computer-Aided Diagnosis Schemes for Vertebral Fractures and Lung Nodules on Chest Radiographs. Am. J. Roentgenol. 191: 260-265 [Abstract] [Full Text]  
• Ishani, A., Blackwell, T., Jamal, S. A., Cummings, S. R., Ensrud, K. E., for the MORE Investigators, (2008). The Effect of Raloxifene Treatment in Postmenopausal Women with CKD. J. Am. Soc. Nephrol. 19: 1430-1438 [Full Text]  
• Karis, R. (2008). Review of Comparative Effectiveness of Treatments to Prevent Fractures. ANN INTERN MED 148: 886-886 [Full Text]  
• Papapoulos, S E, Schimmer, R C (2008). Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Postgrad. Med. J. 84: 307-312 [Abstract] [Full Text]  
• Edwards, B. J., Migliorati, C. A. (2008). Osteoporosis and Its Implications for Dental Patients. Journal of the American Dental Association 139: 545-552 [Abstract] [Full Text]  
• Brufsky, A., Bundred, N., Coleman, R., Lambert-Falls, R., Mena, R., Hadji, P., Jin, L., Schenk, N., Ericson, S., Perez, E. A., Z-FAST and ZO-FAST Study Groups, (2008). Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist 13: 503-514 [Abstract] [Full Text]  
• Martin, T. J., Ng, K. W. (2007). New Agents for the Treatment of Osteoporosis. IBMS BoneKEy 4: 287-298 [Abstract] [Full Text]  
• Kimmel, D.B. (2007). Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates. JDR 86: 1022-1033 [Abstract] [Full Text]  
• Herndon, M. B., Schwartz, L. M., Woloshin, S., Welch, H. G. (2007). Implications Of Expanding Disease Definitions: The Case Of Osteoporosis. Health Aff (Millwood) 26: 1702-1711 [Abstract] [Full Text]  
• Lilleby, V. (2007). Review: Bone status in juvenile systemic lupus erythematosus. Lupus 16: 580-586 [Abstract]  
• Papapoulos, S E, Schimmer, R C (2007). Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66: 853-858 [Abstract] [Full Text]  
• Ma, J., Johns, R. A, Stafford, R. S (2007). Americans are not meeting current calcium recommendations. Am. J. Clin. Nutr. 85: 1361-1366 [Abstract] [Full Text]  
• Gilchrist, N. L., Frampton, C. M., Acland, R. H., Nicholls, M. G., March, R. L., Maguire, P., Heard, A., Reilly, P., Marshall, K. (2007). Alendronate Prevents Bone Loss in Patients with Acute Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled Study. J. Clin. Endocrinol. Metab. 92: 1385-1390 [Abstract] [Full Text]  
• Russell, R. G. G. (2007). Bisphosphonates: Mode of Action and Pharmacology. Pediatrics 119: S150-S162 [Abstract] [Full Text]  
• McClung, M. R. (2007). Bisphosphonate Therapy: To Stop or Not to Stop?. IBMS BoneKEy 4: 78-82 [Full Text]  
• Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., Wehren, L. E., Lombardi, A., Santora, A. C., Cummings, S. R., for the FLEX Research Group, (2006). Effects of Continuing or Stopping Alendronate After 5 Years of Treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial. JAMA 296: 2927-2938 [Abstract] [Full Text]  
• Cummings, S. R. (2006). A 55-Year-Old Woman With Osteopenia. JAMA 296: 2601-2610 [Abstract] [Full Text]  
• Lentle, B., Worsley, D. (2006). Osteoporosis Redux. JNM 47: 1945-1959 [Full Text]  
• Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., Cobelli, C., Toffolo, G., Man, C. D., Tindall, D. J., Melton, L. J. III, Smith, G. E., Khosla, S., Jensen, M. D. (2006). DHEA in Elderly Women and DHEA or Testosterone in Elderly Men. NEJM 355: 1647-1659 [Abstract] [Full Text]  
• Stephenson, A., Jamal, S., Dowdell, T., Pearce, D., Corey, M., Tullis, E. (2006). Prevalence of Vertebral Fractures in Adults With Cystic Fibrosis and Their Relationship to Bone Mineral Density.. Chest 130: 539-544 [Abstract] [Full Text]  
• Finkelstein, J. S., Leder, B. Z., Burnett, S.-A. M., Wyland, J. J., Lee, H., de la Paz, A. V., Gibson, K., Neer, R. M. (2006). Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men. J. Clin. Endocrinol. Metab. 91: 2882-2887 [Abstract] [Full Text]  
• Bonnick, S., Saag, K. G., Kiel, D. P., McClung, M., Hochberg, M., Burnett, S.-A. M., Sebba, A., Kagan, R., Chen, E., Thompson, D. E., de Papp, A. E., for the Fosamax Actonel Comparison Trial (FACT) in, (2006). Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. J. Clin. Endocrinol. Metab. 91: 2631-2637 [Abstract] [Full Text]  
• Liu, H., Michaud, K., Nayak, S., Karpf, D. B., Owens, D. K., Garber, A. M. (2006). The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis.. Arch Intern Med 166: 1209-1217 [Abstract] [Full Text]  
• Nayak, S., Olkin, I., Liu, H., Grabe, M., Gould, M. K., Allen, I. E., Owens, D. K., Bravata, D. M. (2006). Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.. ANN INTERN MED 144: 832-841 [Abstract] [Full Text]  
• Sanchez, A. J., Aranda-Michel, J. (2006). Liver Disease and Osteoporosis. Nutr Clin Pract 21: 273-278 [Abstract] [Full Text]  
• Michaud, L. B., Goodin, S. (2006). Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 63: 534-546 [Abstract] [Full Text]  
• Mobley, L. R., Hoerger, T. J., Wittenborn, J. S., Galuska, D. A., Rao, J. K. (2006). Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate. Med Decis Making 26: 194-206 [Abstract]  
• Wang, C.-J., Wang, J.-W., Ko, J.-Y., Weng, L.-H., Huang, C.-C. (2006). Three-Year Changes in Bone Mineral Density Around the Knee After a Six-Month Course of Oral Alendronate Following Total Knee Arthroplasty. A Prospective, Randomized Study. JBJS 88: 267-272 [Abstract] [Full Text]  
• Liu, R. H., Albrecht, J., Werth, V. P. (2006). Cross-sectional Study of Bisphosphonate Use in Dermatology Patients Receiving Long-term Oral Corticosteroid Therapy. Arch Dermatol 142: 37-41 [Abstract] [Full Text]  
• Helvering, L. M., Liu, R., Kulkarni, N. H., Wei, T., Chen, P., Huang, S., Lawrence, F., Halladay, D. L., Miles, R. R., Ambrose, E. M., Sato, M., Ma, Y. L., Frolik, C. A., Dow, E. R., Bryant, H. U., Onyia, J. E. (2005). Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifene. Mol. Pharmacol. 68: 1225-1238 [Abstract] [Full Text]  
• Adami, S., Pavelka, K., Cline, G. A., Hosterman, M. A., Barton, I. P., Cohen, S. B., Bensen, W. G. (2005). Upper Gastrointestinal Tract Safety of Daily Oral Risedronate in Patients Taking NSAIDs: A Randomized, Double-Blind, Placebo-Controlled Trial. Mayo Clin Proc. 80: 1278-1285 [Abstract]  
• Ho, A. Y., Kung, A. W. (2005). Efficacy and Tolerability of Alendronate Once Weekly in Asian Postmenopausal Osteoporotic Women. The Annals of Pharmacotherapy 39: 1428-1433 [Abstract] [Full Text]  
• McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., Eriksen, E. F. (2005). Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Arch Intern Med 165: 1762-1768 [Abstract] [Full Text]  
• Ward, L. M., Denker, A. E., Porras, A., Shugarts, S., Kline, W., Travers, R., Mao, C., Rauch, F., Maes, A., Larson, P., Deutsch, P., Glorieux, F. H. (2005). Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I. J. Clin. Endocrinol. Metab. 90: 4051-4056 [Abstract] [Full Text]  
• Golden, N. H., Iglesias, E. A., Jacobson, M. S., Carey, D., Meyer, W., Schebendach, J., Hertz, S., Shenker, I. R. (2005). Alendronate for the Treatment of Osteopenia in Anorexia Nervosa: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Clin. Endocrinol. Metab. 90: 3179-3185 [Abstract] [Full Text]  
• Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., Pak, C. Y. C. (2005). Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy. J. Clin. Endocrinol. Metab. 90: 1294-1301 [Abstract] [Full Text]  
• Quandt, S. A., Thompson, D. E., Schneider, D. L., Nevitt, M. C., Black, D. M., Fracture Intervention Trial Research Group, (2005). Effect of Alendronate on Vertebral Fracture Risk in Women With Bone Mineral Density T Scores of -1.6 to -2.5 at the Femoral Neck: The Fracture Intervention Trial. Mayo Clin Proc. 80: 343-349 [Abstract]  
• Papapoulos, S. E. (2005). Long-Term Therapy of Osteoporosis with Bisphosphonates: Evidence and Implications for Daily Practice. IBMS BoneKEy 2: 13-19 [Full Text]  
• McClung, M. R., Wasnich, R. D., Hosking, D. J., Christiansen, C., Ravn, P., Wu, M., Mantz, A. M., Yates, J., Ross, P. D., Santora, A. C. II, on behalf of the Early Postmenopausal Intervention, (2004). Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study. J. Clin. Endocrinol. Metab. 89: 4879-4885 [Abstract] [Full Text]  
• Wenstrup, R. J., Bailey, L., Grabowski, G. A., Moskovitz, J., Oestreich, A. E., Wu, W., Sun, S. (2004). Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104: 1253-1257 [Abstract] [Full Text]  
• Stafford, R. S., Drieling, R. L., Hersh, A. L. (2004). National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003. Arch Intern Med 164: 1525-1530 [Abstract] [Full Text]  
• Bjarnason, N. H., Chan, A. S., Ott, S. M., Ruggiero, S. L., Mehrotra, B., Bone, H. G., Santora, A. C. (2004). Ten Years of Alendronate Treatment for Osteoporosis in Postmenopausal Women. NEJM 351: 190-192 [Full Text]  
• Smith, B J, Laslett, L L, Pile, K D, Phillips, P J, Phillipov, G, Evans, S M, Esterman, A J, Berry, J G (2004). Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chronic Respiratory Disease 1: 131-137 [Abstract]  
• Keegan, T. H.M., Schwartz, A. V., Bauer, D. C., Sellmeyer, D. E., Kelsey, J. L. (2004). Effect of Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Type 2 Diabetic Women: The Fracture Intervention Trial. Diabetes Care 27: 1547-1553 [Abstract] [Full Text]  
• Hwang, R., Lee, E. J., Kim, M. H., Li, S.-Z., Jin, Y.-J., Rhee, Y., Kim, Y. M., Lim, S.-K. (2004). Calcyclin, a Ca2+ Ion-binding Protein, Contributes to the Anabolic Effects of Simvastatin on Bone. J. Biol. Chem. 279: 21239-21247 [Abstract] [Full Text]  
• Strewler, G. J. (2004). Decimal Point -- Osteoporosis Therapy at the 10-Year Mark. NEJM 350: 1172-1174 [Full Text]  
• Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., Liberman, U. A., the Alendronate Phase III Osteoporosis Treatment S, (2004). Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women. NEJM 350: 1189-1199 [Abstract] [Full Text]  
• Evio, S., Tiitinen, A., Laitinen, K., Ylikorkala, O., Valimaki, M. J. (2004). Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis. J. Clin. Endocrinol. Metab. 89: 626-631 [Abstract] [Full Text]  
• Francis, R.M., Baillie, S.P., Chuck, A.J., Crook, P.R., Dunn, N., Fordham, J.N., Kelly, C., Rodgers, A. (2004). Acute and long-term management of patients with vertebral fractures. QJM 97: 63-74 [Abstract] [Full Text]  
• Aris, R. M., Lester, G. E., Caminiti, M., Blackwood, A. D., Hensler, M., Lark, R. K., Hecker, T. M., Renner, J. B., Guillen, U., Brown, S. A., Neuringer, I. P., Chalermskulrat, W., Ontjes, D. A. (2004). Efficacy of Alendronate in Adults with Cystic Fibrosis with Low Bone Density. Am. J. Respir. Crit. Care Med. 169: 77-82 [Abstract] [Full Text]  
• Grados, F., Brazier, M., Kamel, S., Mathieu, M., Hurtebize, N., Maamer, M., Garabedian, M., Sebert, J.-L., Fardellone, P. (2003). Prediction of Bone Mass Density Variation by Bone Remodeling Markers in Postmenopausal Women with Vitamin D Insufficiency Treated with Calcium and Vitamin D Supplementation. J. Clin. Endocrinol. Metab. 88: 5175-5179 [Abstract] [Full Text]  
• Wang, C.-J., Wang, J.-W., Weng, L.-H., Hsu, C.-C., Huang, C.-C., Chen, H.-S. (2003). The Effect of Alendronate on Bone Mineral Density in the Distal Part of the Femur and Proximal Part of the Tibia After Total Knee Arthroplasty. JBJS 85: 2121-2126 [Abstract] [Full Text]  
• Ettinger, M. P. (2003). Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly. Arch Intern Med 163: 2237-2246 [Abstract] [Full Text]  
• Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., Neer, R. M. (2003). The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis. NEJM 349: 1216-1226 [Abstract] [Full Text]  
• Boivin, G., Lips, P., Ott, S. M., Harper, K. D., Sarkar, S., Pinette, K. V., Meunier, P. J. (2003). Contribution of Raloxifene and Calcium and Vitamin D3 Supplementation to the Increase of the Degree of Mineralization of Bone in Postmenopausal Women. J. Clin. Endocrinol. Metab. 88: 4199-4205 [Abstract] [Full Text]  
• Prestwood, K. M., Kenny, A. M., Kleppinger, A., Kulldorff, M. (2003). Ultralow-Dose Micronized 17{beta}-Estradiol and Bone Density and Bone Metabolism in Older Women: A Randomized Controlled Trial. JAMA 290: 1042-1048 [Abstract] [Full Text]  
• Siris, E. S., Bilezikian, J. P., Rubin, M. R., Black, D. M., Bockman, R. S., Bone, H. G., Hochberg, M. C., McClung, M. R., Schnitzer, T. J. (2003). Pins and Plaster Aren't Enough: A Call for the Evaluation and Treatment of Patients with Osteoporotic Fractures. J. Clin. Endocrinol. Metab. 88: 3482-3486 [Abstract] [Full Text]  
• Rodan, G. A., Reszka, A. A. (2003). Osteoporosis and Bisphosphonates. JBJS 85: 8-12 [Full Text]  
• Brown, T. E. R. (2003). Osteoporosis: A Pharmacotherapy Update. Journal of Pharmacy Practice 16: 164-169 [Abstract]  
• Greenspan, S. L., Resnick, N. M., Parker, R. A. (2003). Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial. JAMA 289: 2525-2533 [Abstract] [Full Text]  
• Ma, Y. L., Bryant, H. U., Zeng, Q., Schmidt, A., Hoover, J., Cole, H. W., Yao, W., Jee, W. S. S., Sato, M. (2003). New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats. Endocrinology 144: 2008-2015 [Abstract] [Full Text]  
• Eichner, S. F, Lloyd, K. B, Timpe, E. M (2003). Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment. The Annals of Pharmacotherapy 37: 711-724 [Abstract] [Full Text]  
• Koo, W. W. K., Hammami, M., Margeson, D. P., Nwaesei, C., Montalto, M. B., Lasekan, J. B. (2003). Reduced Bone Mineralization in Infants Fed Palm Olein-Containing Formula: A Randomized, Double-Blinded, Prospective Trial. Pediatrics 111: 1017-1023 [Abstract] [Full Text]  
• Ascott-Evans, B. H., Guanabens, N., Kivinen, S., Stuckey, B. G. A., Magaril, C. H., Vandormael, K., Stych, B., Melton, M. E. (2003). Alendronate Prevents Loss of Bone Density Associated With Discontinuation of Hormone Replacement Therapy: A Randomized Controlled Trial. Arch Intern Med 163: 789-794 [Abstract] [Full Text]  
• Brown, J. P., Josse, R. G. (2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ 168: SF1-38 [Abstract] [Full Text]  
• Riggs, B. L., Hartmann, L. C. (2003). Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice. NEJM 348: 618-629 [Full Text]  
• Watts, N. B., Josse, R. G., Hamdy, R. C., Hughes, R. A., Manhart, M. D., Barton, I., Calligeros, D., Felsenberg, D. (2003). Risedronate Prevents New Vertebral Fractures in Postmenopausal Women at High Risk. J. Clin. Endocrinol. Metab. 88: 542-549 [Abstract] [Full Text]  
• Horwitz, M. J., Tedesco, M. B., Gundberg, C., Garcia-Ocana, A., Stewart, A. F. (2003). Short-Term, High-Dose Parathyroid Hormone-Related Protein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis. J. Clin. Endocrinol. Metab. 88: 569-575 [Abstract] [Full Text]  
• Chow, C. C., Chan, W. B., Li, J. K. Y., Chan, N. N., Chan, M. H. M., Ko, G. T. C., Lo, K. W., Cockram, C. S. (2003). Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism. J. Clin. Endocrinol. Metab. 88: 581-587 [Abstract] [Full Text]  
• Chellaiah, M. A., Kizer, N., Biswas, R., Alvarez, U., Strauss-Schoenberger, J., Rifas, L., Rittling, S. R., Denhardt, D. T., Hruska, K. A. (2003). Osteopontin Deficiency Produces Osteoclast Dysfunction Due to Reduced CD44 Surface Expression. Mol. Biol. Cell 14: 173-189 [Abstract] [Full Text]  
• Malik, A R, Campbell, S H, Toma, N M G (2002). Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 86: 1443-1443 [Full Text]  
• Khan, A. A., Brown, J. P., Kendler, D. L., Leslie, W. D., Lentle, B. C., Lewiecki, E. M., Miller, P. D., Nicholson, R. L., Olszynski, W. P., Watts, N. B. (2002). The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ 167: 1141-1145 [Full Text]  
• Brown, J. P., Josse, R. G. (2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167: s1-34 [Abstract] [Full Text]  
• Galbiati, E., Caruso, P. L., Amari, G., Armani, E., Ghirardi, S., Delcanale, M., Civelli, M. (2002). Pharmacological Actions of a Novel, Potent, Tissue-Selective Benzopyran Estrogen. J. Pharmacol. Exp. Ther. 303: 196-203 [Abstract] [Full Text]  
• Parker, C. R., Blackwell, P. J., Fairbairn, K. J., Hosking, D. J. (2002). Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study. J. Clin. Endocrinol. Metab. 87: 4482-4489 [Abstract] [Full Text]  
• Body, J.-J., Gaich, G. A., Scheele, W. H., Kulkarni, P. M., Miller, P. D., Peretz, A., Dore, R. K., Correa-Rotter, R., Papaioannou, A., Cumming, D. C., Hodsman, A. B. (2002). A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab. 87: 4528-4535 [Abstract] [Full Text]  
• Cryer, B., Bauer, D. C. (2002). Oral Bisphosphonates and Upper Gastrointestinal Tract Problems: What Is the Evidence?. Mayo Clin Proc. 77: 1031-1043 [Abstract]  
• Greenspan, S., Field-Munves, E., Tonino, R., Smith, M., Petruschke, R., Wang, L., Yates, J., de Papp, A. E., Palmisano, J. (2002). Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Study. Mayo Clin Proc. 77: 1044-1052 [Abstract]  
• Nelson, H. D., Helfand, M., Woolf, S. H., Allan, J. D. (2002). Screening for Postmenopausal Osteoporosis: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 137: 529-541 [Abstract] [Full Text]  
• Dobrucali, A., Tobey, N. A., Awayda, M. S., Argote, C., Abdulnour-Nakhoul, S., Shao, W., Orlando, R. C. (2002). Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 283: G576-G586 [Abstract] [Full Text]  
• Tuck, S P, Francis, R M (2002). Osteoporosis. Postgrad. Med. J. 78: 526-532 [Abstract] [Full Text]  
• Gardner, M. J., Flik, K. R., Mooar, P., Lane, J. M. (2002). Improvement in the Undertreatment of Osteoporosis Following Hip Fracture. JBJS 84: 1342-1348 [Abstract] [Full Text]